LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA® in Chinese healthy male subjects

• Main Authors: Guoying Cao (Author), Jingjing Wang (Author), Jinjie He (Author), Yingying Hu (Author), Haijing Yang (Author), Linling Que (Author), Xianghong Gu (Author), Jicheng Yu (Author), Xiaojie Wu (Author), Jufang Wu (Author), Wei Fang (Author), Qing He (Author), Jing Zhang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: This study aimed to investigate the pharmacokinetics, safety, and immunogenicity of recombinant humanized anti-human IL-6R monoclonal antibody injection, LZM008, and evaluate the pharmacokinetic similarity between LZM008 and tocilizumab (ACTEMRA®) in Chinese healthy male subjects.Researc...